Stock Events

Stock Events

Insmed 

$157.8
100
+$0.93+0.59% Today

Statistics

Day High
159.47
Day Low
154.48
52W High
211.41
52W Low
64.81
Volume
2,620,973
Avg. Volume
3,054,629
Mkt Cap
33.65B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.94
-1.65
-1.35
-1.06
Expected EPS
-1.05868
Actual EPS
N/A

Financials

-251.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
727.41MRevenue
-1.83BNet Income

Analyst Ratings

$195.14Average Price Target
The highest estimate is 241.00.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
93%
Hold
7%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INSM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for cystic fibrosis, a market that Insmed is targeting with its therapies.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes in the biopharmaceutical space, focusing on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, overlapping with Insmed's focus on serious and rare diseases.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes with Insmed in the area of cystic fibrosis and other serious health conditions through its robust pipeline of biopharmaceuticals.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a competitor due to its focus on developing monoclonal antibodies for the treatment of rare diseases, a similar focus area as Insmed.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes with Insmed in the respiratory disease market, including treatments for conditions like asthma and COPD.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the biopharmaceutical space focusing on neurological diseases, overlapping with Insmed's interest in rare diseases.
AMGEN
AMGN
Mkt Cap160.66B
Amgen competes with Insmed through its development of treatments for serious illnesses, including those in the respiratory and inflammation areas.
Novartis
NVS
Mkt Cap237.61B
Novartis competes with Insmed in the healthcare sector, focusing on innovative medicines for various diseases, including respiratory.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV competes with Insmed in the development of novel modes of action for diseases with high unmet medical need, including cystic fibrosis.

About

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Show more...
CEO
Mr. William H. Lewis J.D., M.B.A.
Employees
1271
Country
US
ISIN
US4576693075

Listings

MI
IT
1INSM.MI
F
DE
IM8N.F
XNAS
US
INSM
MX
MX
INSM.MX

0 Comments

Share your thoughts

FAQ

What is Insmed stock price today?▼
The current price of INSM is $157.8 USD — it has increased by +0.59% in the past 24 hours. Watch Insmed stock price performance more closely on the chart.
What is Insmed stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Insmed stocks are traded under the ticker INSM.
Is Insmed stock price growing?▼
INSM stock has fallen by -2.14% compared to the previous week, the month change is a -11.75% fall, over the last year Insmed has showed a +104.1% increase.
What is Insmed market cap?▼
Today Insmed has the market capitalization of 33.65B
When is the next Insmed earnings date?▼
Insmed is going to release the next earnings report on February 19, 2026.
What were Insmed earnings last quarter?▼
INSM earnings for the last quarter are -1.75 USD per share, whereas the estimation was -1.33 USD resulting in a -31.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Insmed revenue for the last year?▼
Insmed revenue for the last year amounts to 727.41M USD.
What is Insmed net income for the last year?▼
INSM net income for the last year is -1.83B USD.
How many employees does Insmed have?▼
As of February 02, 2026, the company has 1,271 employees.
In which sector is Insmed located?▼
Insmed operates in the Health Care sector.
When did Insmed complete a stock split?▼
The last stock split for Insmed was on March 03, 2011 with a ratio of 1:10.
Where is Insmed headquartered?▼
Insmed is headquartered in Bridgewater, US.